Catalyst Event
Eli Lilly and Co (LLY) · Other
From KEDI U.S. Quality500 + Monthly 1% Premium Index(NTR) (KUSQL500P)
4/30/2026, 12:00:00 AM
The U.S. FDA proposed removing tirzepatide, the active ingredient in Mounjaro and Zepbound, from the bulk drug substances list on 2026-04-30, restricting compounded versions. This regulatory protection of market share is estimated to result in a >10% price impact.
Korean Translation
2026년 4월 30일, 미국 FDA가 티르제파티드를 대량 원료의약품 목록에서 제외 제안하여 복제약 제조를 제한함. 시장 점유율 보호 효과로 인해 10% 이상의 주가 영향이 예상됨.
Related Recent Events
Bristol-Myers Squibb Co (BMY) · Other
The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of August 17, 2026, for its decision on iberdomide for relapsed or refractory multiple myeloma, scheduled. Low impact estimated as the target date is a procedural milestone.
8/17/2026, 12:00:00 AM
Blackstone Inc (BX) · Earnings Release
Blackstone is scheduled to release its Q2 2026 earnings results, with analysts forecasting earnings of approximately $1.34-$1.36 per share, scheduled.
7/23/2026, 12:00:00 AM
Union Pacific Corp (UNP) · Earnings Release
Q2 2026 earnings release is scheduled. Low impact estimated as the date announcement is a routine event; scheduled.
7/23/2026, 12:00:00 AM
Goldman Sachs Group Inc (The) (GS) · Earnings Release
Goldman Sachs' Q2 2026 earnings release is scheduled.
7/14/2026, 12:00:00 AM
NIKE Inc (NKE) · Earnings Release
Q4 Fiscal Year 2026 earnings release is scheduled for June 25, 2026. Low importance as the announcement of the date typically has a minimal market impact.
6/25/2026, 12:00:00 AM
Vistra Corp (VST) · Other
Quarterly dividend of $0.2290 per share with an ex-dividend date of June 22, 2026; low importance estimated as dividends usually cause minor price adjustments, scheduled.
6/22/2026, 12:00:00 AM